183 related articles for article (PubMed ID: 18717608)
1. Adjuvant high-dose intravenous immunoglobulin therapy can be easily and safely introduced as an alternative treatment in patients with severe pemphigus vulgaris: a retrospective preliminary study.
Mignogna MD; Leuci S; Fedele S; Ruoppo E; Adamo D; Russo G; Pagliuca R
Am J Clin Dermatol; 2008; 9(5):323-31. PubMed ID: 18717608
[TBL] [Abstract][Full Text] [Related]
2. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris.
Sami N; Qureshi A; Ruocco E; Ahmed AR
Arch Dermatol; 2002 Sep; 138(9):1158-62. PubMed ID: 12224976
[TBL] [Abstract][Full Text] [Related]
3. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment.
Ahmed AR
J Am Acad Dermatol; 2001 Nov; 45(5):679-90. PubMed ID: 11606916
[TBL] [Abstract][Full Text] [Related]
4. IVIG therapy in pemphigus vulgaris has corticosteroid-sparing and immunomodulatory effects.
Svecova D
Australas J Dermatol; 2016 May; 57(2):141-4. PubMed ID: 26581165
[TBL] [Abstract][Full Text] [Related]
5. Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris.
Engineer L; Bhol KC; Ahmed AR
J Am Acad Dermatol; 2000 Dec; 43(6):1049-57. PubMed ID: 11100022
[TBL] [Abstract][Full Text] [Related]
6. The role of IVIg treatment in severe pemphigus vulgaris.
Baum S; Scope A; Barzilai A; Azizi E; Trau H
J Eur Acad Dermatol Venereol; 2006 May; 20(5):548-52. PubMed ID: 16684282
[TBL] [Abstract][Full Text] [Related]
7. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: Preliminary retrospective study with a seven year follow-up.
Ahmed AR; Nguyen T; Kaveri S; Spigelman ZS
Int Immunopharmacol; 2016 May; 34():25-31. PubMed ID: 26919279
[TBL] [Abstract][Full Text] [Related]
8. An 'n-of-1' placebo-controlled crossover trial of intravenous immunoglobulin as adjuvant therapy in refractory pemphigus vulgaris.
Arnold DF; Burton J; Shine B; Wojnarowska F; Misbah SA
Br J Dermatol; 2009 May; 160(5):1098-102. PubMed ID: 19222460
[TBL] [Abstract][Full Text] [Related]
9. Four mild but refractory cases of pemphigus foliaceus successfully treated with intravenous immunoglobulin.
Kawakami T; Koga H; Saruta H; Ueda A; Inoue Y; Soma Y; Ishii N; Hashimoto T
J Dermatol; 2013 Nov; 40(11):869-73. PubMed ID: 24127870
[TBL] [Abstract][Full Text] [Related]
10. Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus.
Sami N; Qureshi A; Ahmed AR
Eur J Dermatol; 2002; 12(2):174-8. PubMed ID: 11872417
[TBL] [Abstract][Full Text] [Related]
11. Retrospective analysis of a single-center clinical experience toward development of curative treatment of 123 pemphigus patients with a long-term follow-up: efficacy and safety of the multidrug protocol combining intravenous immunoglobulin with the cytotoxic immunosuppressor and mitochondrion-protecting drugs.
Grando SA
Int J Dermatol; 2019 Jan; 58(1):114-125. PubMed ID: 30047585
[TBL] [Abstract][Full Text] [Related]
12. High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases.
Segura S; Iranzo P; Martínez-de Pablo I; Mascaró JM; Alsina M; Herrero J; Herrero C
J Am Acad Dermatol; 2007 Jun; 56(6):960-7. PubMed ID: 17368865
[TBL] [Abstract][Full Text] [Related]
13. Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional therapy.
Ahmed AR; Sami N
J Am Acad Dermatol; 2002 Jan; 46(1):42-9. PubMed ID: 11756944
[TBL] [Abstract][Full Text] [Related]
14. Pemphigus vulgaris: the role of IL-1 and IL-1 receptor antagonist in pathogenesis and effects of intravenous immunoglobulin on their production.
Bhol KC; Desai A; Kumari S; Colon JE; Ahmed AR
Clin Immunol; 2001 Aug; 100(2):172-80. PubMed ID: 11465946
[TBL] [Abstract][Full Text] [Related]
15. Rituximab and intravenous immunoglobulin as alternatives to long-term systemic corticosteroids in the treatment of pemphigus: a single center case series of 63 patients.
Brown AE; Motaparthi K; Hsu S
Dermatol Online J; 2018 Jan; 23(12):. PubMed ID: 29447653
[TBL] [Abstract][Full Text] [Related]
16. Cytokine profiles in pemphigus vulgaris patients treated with intravenous immunoglobulins as compared to conventional immunosuppressive therapy.
Keskin DB; Stern JN; Fridkis-Hareli M; Razzaque Ahmed A
Cytokine; 2008 Mar; 41(3):315-21. PubMed ID: 18289869
[TBL] [Abstract][Full Text] [Related]
17. Intravenous immunoglobulin therapy in autoimmune mucocutaneous blistering diseases: a review of the evidence for its efficacy and safety.
Gürcan HM; Jeph S; Ahmed AR
Am J Clin Dermatol; 2010; 11(5):315-26. PubMed ID: 20642294
[TBL] [Abstract][Full Text] [Related]
18. Use of intravenous immunoglobulin therapy during pregnancy in patients with pemphigus vulgaris.
Ahmed AR; Gürcan HM
J Eur Acad Dermatol Venereol; 2011 Sep; 25(9):1073-9. PubMed ID: 21143649
[TBL] [Abstract][Full Text] [Related]
19. Effect of intravenous immunoglobulin on prednisone dose in patients with pemphigus vulgaris.
Mittmann N; Chan B; Knowles S; Mydlarski PR; Cosentino L; Shear N
J Cutan Med Surg; 2006; 10(5):222-7. PubMed ID: 17234105
[TBL] [Abstract][Full Text] [Related]
20. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.
Gürcan HM; Ahmed AR
Ann Pharmacother; 2007 Oct; 41(10):1604-10. PubMed ID: 17785614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
